medigraphic.com
ISSN 1561-3062 (Electronic)

2014, Number 1

<< Back Next >>

Revista Cubana de Obstetricia y Ginecología 2014; 40 (1)

Chlamydia trachomatis: a cofactor in the etiology of cervical cancer

Frontela NM, Rodríguez MY, Ríos HMÁ, Hernández MM

Language: Spanish
References: 54
Page: 68-78
PDF size: 143.56 Kb.


ABSTRACT

It has been shown that human papillomavirus presence is a necessary condition for the development of cervical cancer. However, it is not sufficient and only a small number of exposed women will progress to cervical neoplasia. Proposed cofactors include other sexually transmitted infections, smoking habit, hormones, nutritional deficiencies, obesity and host genetic/immunologic responses. Chlamydia trachomatis is the most common bacterial sexually transmitted infection and it has been associated with the development of cervical cancer in many case-controlled and population based studies. However, it is still necessary to elucidate some aspects of cause/effect relationship between Chlamydia trachomatis infection, human papillomavirus persistence and progression to cervical cancer. This article aims to review the current scientific literature upon the role of Chlamydia trachomatis as a cofactor in the development of invasive cervical cancer and HPV establishment. Prophylaxis against Chlamydia trachomatis could be important in reducing the incidence of cervical cancer, mainly in young women.


REFERENCES

  1. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012 Nov 20;30 Suppl 5:F12-23.

  2. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. Int J Cancer. 2007;13:621-32.

  3. Ministerio de Salud Pública. Anuario estadístico de salud. Dirección Nacional de Registros médicos y estadísticas de salud. La Habana: MINSAP; 2012. p. 68-107.

  4. Colectivo de autores. Programa Nacional de Diagnóstico Precoz del Cáncer Cérvicouterino. La Habana: MINSAP; 2001.

  5. Papanicolaou GN, Traut HF. The diagnostic value of vaginal smears in carcinoma of the uterus. American Journal of Obstetrics and Gynecology. 1941;42:193.

  6. Colectivo de autores. Revisión del Programa Nacional de Diagnóstico Precoz del Cáncer Cérvicouterino. Unidad independiente para el control del cáncer. La Habana: MINSAP. 2011.

  7. Natphopsuk S, Settheetham-Ishida W, Sinawat S, Pientong C, Yuenyao P, Ishida T. Risk factors for cervical cancer in northeastern Thailand: detailed analyses of sexual and smoking behavior. Asian Pac J Cancer Prev. 2012;13(11):5489-95.

  8. Remschmidt C, Kaufmann AM, Hagemann I, Vartazarova E, Wichmann O, Deleré Y. Risk factors for cervical human papillomavirus infection and high-grade intraepithelial lesion in women aged 20 to 31 years in Germany. Int J Gynecol Cancer 2013;23(3):519-26.

  9. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244-65.

  10. Fonseca-Moutinho JA. Smoking and cervical cancer. ISRN Obstet Gynecol; 2011:8476-84.

  11. Brunham RC, Rekart ML. Considerations on Chlamydia trachomatis disease expression. FEMS Immunol Med Microbiol. 2009;55:162-6.

  12. Smith JS, Muñoz N, Herrero R. Evidence for Chlamydia trachomatis as a Human papillomavirus cofactor in the etiology of invasive cervical cancer in Brazil and Philippines. J Infect Dis. 2002;185:324-31.

  13. Maruthur NM, Bolen SD, Brancati FL, Clark JM. The association of obesity and cervical cancer screening: a systematic review and meta-analysis. Obesity (Silver Spring). 2009;17(2):375-81.

  14. Bodily J, Laimins LA. Persistence of human papillomavirus infection: keys to malignant progression. Trends Microbiol. 2011;19(1):33-9.

  15. Brinton L, Schiffman M. Epidemiology of gynecologic cancers. In: Barakat R, Markman M, Randall M, eds. Principles and Practice of Gynecologic Oncology. 5th edn. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2009.

  16. Wright T. Pathogenesis and diagnosis of preinvasive lesions of the lower genital tract. In: Barakat R, Markman M, Randall M, eds. Principles and Practice of Gynecologic Oncology. 5th edn. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2009.

  17. Castle PE, Schiffman M, Herrero R, Hildesheim A, Rodriguez AC, Bratti MC, et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis. 2005;191(11):1808-16.

  18. Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang T, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis. 1994;169(2):235-40.

  19. Furumoto H, Irahara M. Human papillomavirus (HPV) and cervical cancer. J Med Invest. 2002;49(3-4):124-33.

  20. Sharma A, Pratap M, Sawhney VM, Khan IU, Bhambhani S, Mitra AB. Frequent amplification of CerbB2(Her-2/Neu) oncogen in cervical carcinomas as detected by non-fluorescence in situ hybridization technique on paraffin sections. Oncology. 1999;56(1):83-7.

  21. Koutsky L. The epidemiology behind the HPV vaccine discovery. Annual Epidemiology. 2009;19:239-44.

  22. Landro ME, Dalbert D, Picconi MA, Cúneo N, González J, Vornetti S, et al. Human papillomavirus and mutated H-ras oncogene in cervical carcinomas and pathological negative pelvic lymph nodes: a retrospective follow-up. J Med Virol. 2008;80(4):694-701.

  23. Pérez-Sayáns M, Suárez-Peñaranda JM, Pilar GD, Barros-Angueira F, Gándara- Rey JM, García-García A. What real influence does the proto-oncogene c-myc have in OSCC behavior? Oral Oncol. 2011;47(8):688-92.

  24. Steenbergen RDM, de Wilde J, Wilting SM, Brink ATP, Snijders PJF, Meijer CJLM. HPV-mediated transformation of the anogenital tract. Review. Journal of Clinical Virology. 2005;32S:S25S33.

  25. Simonetti AC, Melo JHL, De'Souza PRE, Bruneska D, Filho JLDL. Immunological's host profile for HPV and Chlamydia trachomatis, a cervical cancer cofactor. Microbes and Infection. 2009;11:435-42.

  26. World Health Organization. Sexually transmitted diseases. Department of Reproductive Health and Research, World Health Organization. Research on Reproductive Health at WHO. Biennial Report 2000-2001. Chapter 3: Preventing reproductive tract infections. Geneva: WHO; 2002. p. 31-36.

  27. Stamm WE. Chlamydia trachomatis infections of the adult. In: Holmes KK, Sparling PF, Stamm WE, editors. Sexually transmitted diseases. New York: Mc Graw-Hill Medical; 2008. p. 575-94.

  28. Stamm WE. Chlamydia trachomatis-the persistent pathogen: Thomas Parran Award Lecture. Sex Transm Dis. 2001;28(12):684-9.

  29. Agrawal T, Vats V, Salhan S, Mittal A. The mucosal immune response to Chlamydia trachomatis infection of the reproductive tract in women. Journal of Reproductive Immunology. 2009;83:173-8.

  30. Paavonen J, Vesterinen E, Meyer B, Saikku P, Suni J, Purola E, et al. Genital Chlamydia trachomatis infections in patients with cervical atypia. Obstet Gynecol. 1979;54:289-91.

  31. Schacher J, Hill EC, King EB, Coleman UR, Jones P, Meyer KF. Chlamydial infection in woman with cervical dysplasia. Am J Obstet Gynecol. 1975;123(7):753-7.

  32. Koskela P, Anttila T, Björge T, Brunsvig A, Dillner J, Hakama M, et al. Chlamydia trachomatis infection and invasive cervical cancer. Int J Cancer. 2000;85:35-9.

  33. Wallin KL, Wiklund F, Luostarinen T. A population-based prospective study of Chlamydia trachomatis infection and cervical carcinoma. Int J Cancer. 2002;101:371e4.

  34. Quint KD, de Koning MN, Geraets DT. Comprehensive analysis of HumanPapillomavirus and Chlamydia trachomatis in in-situ and invasive cervical adenocarcinoma. Gynecol Oncol. 2009;114:390e4.

  35. Paavonen J, Karunakaran KP, Noguchi Y, Anttila T, Bloigu A, Dillner J, et al. Serum antibody response to the heat shock protein 60 of Chlamydia trachomatis in women with developing cervical cancer. Am J Obstet Gynecol. 2003;189:1287-92.

  36. Paavonen J, Purola E. Cytological findings in cervical chlamydial infection. Med Biol. 1980;58(3):174-8.

  37. Agrawal T, Vats V, Wallace PK Salhan S, Mittal A. Role of cervical dendritic cell subsets, co-stimulatory molecules, cytokine secretion profile and beta-estradiol in development of sequalae to Chlamydia trachomatis infection. Reprod Biol Endocrinol. 2008;6:46.

  38. Velicer C, Zhu X, Vuocolo S, Liaw KL, Saah A. Prevalence and incidence of HPV genital infection in women. Sex Transm Dis. 2009;36(11):696-703.

  39. Lehtinen M, Ault KA, Lyytikainen E, Dillner J, Garland SM, Ferris DG, et al. Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia. Sex Transm Infect. 2011;87(5):372-6.

  40. Hafner L, Beagley K, Timms P. Chlamydia trachomatis infection: host immune responses and potential vaccines. Mucosal Immunology 2008;1(2):116-30.

  41. Smith JS, Bosetti C, Muñoz N, Herrero R, Bosch FX, Eluf-Neto J, et al. Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study. Int J Cancer. 2004;111(3):431-9.

  42. Silins I, Ryd W, Strand A, Wadell G, Törnberg S, Hansson BG, et al. Chlamydia trachomatis infection and persistence of human papillomavirus. Int J Cancer 2005;116(1):110-15.

  43. Luostarinen T, Lehtinen M, Bjorge T, Abeler V, Hakama M, Hallmans G, et al. Joint effects of different human papillomaviruses and Chlamydia trachomatis infections on risk of squamous cell carcinoma of the cervix uteri. Eur J Cancer. 2004;40(7):1058-65.

  44. Belland RJ, Scidmore MA, Crane DD, Hogan DM, Whitmire W, McClarty G, et al. Chlamydia trachomatis cytotoxicity associatted with complete and partial cytotoxin genes. Proc Natl Acad Sci USA. 2001;98(24):13984-9.

  45. Chiarini F, Pisani S, Gallinelli C, Papi E, Seganti L, Degener AM, et al. Simultaneous detection of HPV and other sexually transmitted agents in chronic urethritis. Minerva Urol Nefrol. 1998;50(4):225-31.

  46. Prozialeck WC, Fay MJ, Lamar PC, Pearson CA, Sigar I, Ramsey KH. Chlamydia trachomatis disrupts N-cadherin-dependet cell-cell junctions and sequesters betacatenin in human cervical epithelial cells. Infect Immunol. 2002;70(5):2605-13.

  47. Schlott T, Eiffert H, Bohne W, Landgrebe J, Brunner E, Spielbauer B, et al. Chlamydia trachomatis modulates expression of tumor suppressor gene caveolin-1 and oncogen C-myc in the transformation zone of non-neoplastic cervical tissue. Gynecol Oncol. 2005;98(3):409-19.

  48. Al Moustafa AE, Foulkers WD, Benlimame N, Wong A, Yen L, Bergeron J, et al. E6/E7 proteins of HPV type 16 and ErbB-2 cooperaye to induce neoplastic transformation of primary normal oral epithelial cells. Oncogene. 2004;23(2):350- 8.

  49. Safaeian M, Quint K, Schiffman M, Rodriguez AC, Wacholder S, Herrero R, et al. Chlamydia trachomatis and Risk of Prevalent and Incident Cervical Premalignancy in a Population-Based Cohort. J Natl Cancer Inst 2010;102:1794-1804.

  50. Lihtinen M, Ault KA, Lyytikaainen E, Dillner J, Garland SM, Ferris DG, et al. Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia. Sex Transm Infect. 2011;87(5):372-6.

  51. Bhatla N, Puri K, Joseph E, Kriplani A, Iyer VK, Sreenicas V. Association of Chlamydia trachomatis infection with human papillomavirus (HPV) and cervical intraepithelial neoplasia A pilot study. Indian J Med Res. 2013;137:533-9.

  52. Lehtinen M, Lyytikä i nen E, Koskela P, Surcel H-M, Paavonen J. Chlamydia trachomatis and risk for cervical neoplasia-a meta-analysis of longitudinal studies. Proceedings of the Twelfth International Symposium on Human Chlamydial Infections, International Chlamydia Symposium, Salzburg, Austria, 20-25 June 2010. Abstract. p. 445-8.

  53. Paavonen J. Chlamydia trachomatis infections of the female genital tract: State of the art. Annals of Medicine. 2012;44:18-28.

  54. Vaccarella S, Lortet-Tieulent J, Plummer M, Franceschi S, Bray F. Worldwide trends in cervical cancer incidence: Impact of screening against changes in disease risk factors. Eur J Cancer. 2013 Jun 7.




2020     |     www.medigraphic.com